Additionally, it proposes the necessity of therapies that amplify the reduced systemic T cells and induce a tumor-reactive composition of CD8 T cells within the tumor, ensuring an adequate stem-like subset highly responsive to anti-PD-1. The gene discussed is PDCD1; the disease is neoplasm.